I-POU:POUドメインのタンパク質で,ニューロン特異的な遺伝子活性化を阻害する
M N Treacy1, X He, M G Rosenfeld
1Eukaryotic Regulatory Biology Program, University of California, San Diego School of Medicine, La Jolla 92093-0648.
Nature
|April 18, 1991
まとめ
新種のタンパク質であるI-POUは,別のタンパク質であるCf1-a.と結合することで,神経細胞の遺伝子活性化を抑制する. この発見は,発達中の遺伝子発現を制御するための新しいメカニズムを明らかにしています.
科学分野:
- 発達生物学 発達生物学とは
- 分子遺伝学 分子遺伝学
- 神経科学は神経科学である.
背景:
- POUドメインのタンパク質は,特にニューロンにおける遺伝子転写を調節する.
- 特定のPOUタンパク質は,神経細胞特有の遺伝子の活性化剤として作用する.
研究 の 目的:
- 神経細胞の遺伝子調節に関与する新しいPOUドメインのタンパク質を特定し,特徴づけること.
- I-POUが転写活性化を阻害するメカニズムを解明する.
主な方法:
- ドロソフィラのPOUドメインタンパク質I-POUとCf1-a.の共表現分析
- タンパク質複合体の形成を評価するためのヘテロディメリゼーション研究.
- Cf1-a DNA結合に対するI-POUの効果を評価するためのDNA結合測定法.
- ドーパ-デカルボキシラーゼ遺伝子プロモーターを用いたトランザクティベーションアッセイ.
主要な成果:
- 新しいPOUドメインタンパク質,I-POUが特定されました.
- I-POUは,特定のホームドメイン変異により,DNA結合能力が欠けている.
- I-POUは,POUの活性化タンパク質Cf1-a.と安定したヘテロダイマーを形成する.
- この複雑な形成は,Cf1-aがDNAに結合し,ドーパ-デカルボキシラーゼ遺伝子の転写を活性化するのを防ぐ.
結論:
- I-POUは,Cf1-a.のDNA結合活性を抑制することによって抑制剤として作用します.
- これは,DNAに結合しないPOUドメインタンパク質を含む新しい遺伝子調節メカニズムを表しています.
- このメカニズムは,神経発達中の遺伝子活性化を制御するための戦略を提供します.
関連する概念動画
Prokaryotic Transcriptional Activators and Repressors
The organization of prokaryotic genes in their genome is notably different from that of eukaryotes. Prokaryotic genes are organized, such that the genes for proteins involved in the same biochemical process or function are located together in groups. This group of genes, along with their regulatory elements, are collectively known as an operon. The functional genes in an operon are transcribed together to give a single strand of mRNA known as polycistronic mRNA.
Transcription of prokaryotic...
Transcription of prokaryotic...
Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Prokaryotic Transcriptional Activators and Repressors
The organization of prokaryotic genes in their genome is notably different from that of eukaryotes. Prokaryotic genes are organized, such that the genes for proteins involved in the same biochemical process or function are located together in groups. This group of genes, along with their regulatory elements, are collectively known as an operon. The functional genes in an operon are transcribed together to give a single strand of mRNA known as polycistronic mRNA.
Transcription of prokaryotic...
Transcription of prokaryotic...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...


